EVH Stock Recent News
EVH LATEST HEADLINES
Evolent's revenue dip in Q1 was structural, not demand-driven, and Q2 shows stabilization; I expect growth to resume in the second half of 2025. New specialty contracts, incremental member growth, and key leadership appointments should drive recovery and enhance clinical and financial credibility. The oversubscribed convertible notes offering signals investor confidence, strengthens liquidity, and supports shareholder value through buybacks and reduced refinancing risk.
WASHINGTON , Aug. 19, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced the pricing of $145.0 million aggregate principal amount of 4.50% convertible senior notes due 2031. The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
WASHINGTON , Aug. 18, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced that it intends to offer $140.0 million aggregate principal amount of convertible senior notes due 2031, subject to market and other conditions. Evolent also expects to grant the initial purchasers in the proposed offering an option to purchase up to an additional $20.0 million aggregate principal amount of notes.
Evolent Health, Inc. (NYSE:EVH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants John Paul Johnson - Chief Financial Officer Seth Barrie Blackley - Co-Founder, CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division Eduardo Enrique Ron - Truist Securities, Inc., Research Division Jared Phillip Haase - William Blair & Company L.L.C.
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Evolent Health (EVH) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of $0.09. This compares to earnings of $0.3 per share a year ago.
WASHINGTON , Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year.
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company to Participate in Upcoming Conferences WASHINGTON , July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.